DuPont gains rights to production, marketing and sales of AB-Life while AB-Biotics conducts further clinical research
DuPont Nutrition & Health and AB-Biotics have signed a global collaboration and licensing agreement on AB-Life, a probiotic that is clinically documented to maintain healthy levels of cholesterol in at-risk individuals.
Under the agreement, DuPont will have exclusive rights to the production, marketing and sales of AB-Life while AB-Biotics will continue to conduct clinical research to further substantiate the health benefits of AB-Life.
AB-Life is a patented probiotic formulation developed by AB-Biotics, in Barcelona, Spain. DuPont will integrate AB-Life into its HOWARU probiotic range for the dietary supplement and food and beverage industries.
The company expects to launch the product in this year\'s fourth quarter.
The AB-Life strain will complement the DuPont portfolio for cardiovascular health
\'Probiotics is a fast-growing segment of our business as people increasingly experience the benefits they can provide,\' said Fabienne Saadane-Oaks, Vice President Health and Protection at DuPont Nutrition & Health.
DuPont will integrate AB-Life into its HOWARU probiotic range
\'Our HOWARU formulations have been clinically tested and shown to deliver the digestive and immune support people need, and we are looking forward to adding cardiovascular support to our probiotics portfolio.\'
The new probiotic will complement DuPont’s portfolio for cardiovascular health, which includes Danisco Pinvita phytosterols and Danisco Evesse EPC, a natural apple extract and soy protein to address the needs of a global healthy ageing population.
\'This agreement marks a significant milestone for AB-Biotics and proves the high value of our patented probiotics and other functional ingredients for the dietary supplement and food and beverage industries,\' said Miquel Angel Bonachera and Sergi Audivert, CEOs of AB-Biotics. \'Thanks to DuPont we can bring AB-Life to this market with a top-positioned partner.\'
The global retail market for probiotics is estimated at US$32bn and is expected to grow to $45bn in 2018. More than 90% of the total is attributed to food, beverage and dietary supplements.